Search Results - "O’Sullivan, Hazel"

Refine Results
  1. 1

    FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways by Kelleher, Fergal C, O'Sullivan, Hazel

    Published in Oncotarget (05-07-2016)
    “…FOXM1 is a pro-proliferative transcription factor that promotes cell cycle progression at the G1-S, and G2-M transitions. It is activated by phosphorylation…”
    Get full text
    Journal Article
  2. 2

    Characterization of sebaceous and non-sebaceous cutaneous manifestations in patients with lynch syndrome: a systematic review by Aziz, Shahram, O’Sullivan, Hazel, Heelan, Kara, Alam, Afrina, McVeigh, Terri P.

    Published in Familial cancer (01-04-2023)
    “…A subset of patients with Lynch Syndrome demonstrates cutaneous manifestations of the disorder. Characterization of these Lynch-related skin lesions could help…”
    Get full text
    Journal Article
  3. 3

    Optimising oncology drug expenditure in Ireland by Kieran, Ruth, Hennessy, Maeve, Coakley, Kate, O’Sullivan, Hazel, Cronin, Tim, Lynch, Daire, Mulroe, Eibhlin, Cooke, Katie, Collins, Dearbhaile, O’Reilly, Seamus

    Published in Irish journal of medical science (01-08-2024)
    “…A combination of improvements in patient survival, increasing treatment duration, and the development of more expensive agents has led to a doubling of…”
    Get full text
    Journal Article
  4. 4

    Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer by Aktas, Burak Y, Taban, Hakan, Aksoy, Sercan, O’Sullivan, Hazel, Collins, Dearbhaile, O’Reilly, Seamus, Altundag, Kadri, Schmid, Peter, Chui, Stephen Y, Emens, Leisha A

    Published in The New England journal of medicine (07-03-2019)
    “…To the Editor: In the IMpassion130 trial, Schmid et al. (Nov. 29 issue) 1 found that combination therapy with atezolizumab plus nanoparticle albumin-bound…”
    Get full text
    Journal Article
  5. 5

    Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report by d'Arienzo, Paolo Davide, Cunningham, Niamh, O’Sullivan, Hazel, Grieco, Charlotte, Patel, Virjen, Popat, Sanjay

    Published in JTO clinical and research reports (01-12-2023)
    “…Selpercatinib and pralsetinib are RET inhibitors with substantial activity in advanced RET-rearranged NSCLC. We present a case of pralsetinib-related…”
    Get full text
    Journal Article
  6. 6

    Oxford and the Savannah: Can the Hippo Provide an Explanation for Peto's Paradox? by KELLEHER, Fergal C, O'SULLIVAN, Hazel

    Published in Clinical cancer research (01-02-2014)
    “…Peto's paradox is the counterintuitive finding that increasing body mass and thereby cell number does not correlate with an increase in cancer incidence across…”
    Get full text
    Journal Article
  7. 7
  8. 8
  9. 9

    Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions by O'Sullivan, Hazel M, Feber, Andrew, Popat, Sanjay

    Published in OncoTargets and therapy (01-01-2023)
    “…Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease…”
    Get full text
    Journal Article
  10. 10

    Atezolizumab in patients with advanced non-small-cell lung cancer who are platinum-doublet ineligible by O'Sullivan, Hazel, Popat, Sanjay

    Published in The Lancet (British edition) (05-08-2023)
    “…Before these inhibitors, 5-year survival rates were 0% for stage IVB disease1 but now approach 20% in those without substantial comorbidities and Eastern…”
    Get full text
    Journal Article
  11. 11

    Updates in Management of Malignant Pleural Mesothelioma by John, Alexius, O’Sullivan, Hazel, Popat, Sanjay

    Published in Current treatment options in oncology (01-12-2023)
    “…Opinion statement Malignant pleural mesothelioma (MPM) is an aggressive asbestos-associated thoracic malignancy that is usually incurable. As demonstrated in…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    BRAF inhibitor treatment of melanoma causing colonic polyps:An alternative hypothesis by Kelleher, Fergal C, Callaghan, Grainne, Gallagher, Catriona, O’Sullivan, Hazel

    Published in World journal of gastroenterology : WJG (07-05-2017)
    “…Colonic polyps may arise from BRAF inhibitor treatment of melanoma, possibly due paradoxical activation of the mitogen-activated protein(MAP)-kinase pathway…”
    Get full text
    Journal Article
  18. 18

    “The third wing of the plane”: Fathers' perceptions of their role in the treatment process for daughters with eating disorders by O'Sullivan, Hazel, Goodwin, John, O'Malley, Maria, Happell, Brenda, O'Donovan, Aine

    “…Eating disorders are complex mental health conditions exacerbated by high mortality rates. International and national guidelines recommend family involvement…”
    Get full text
    Journal Article
  19. 19
  20. 20